Zoetis’ (ZTS) Market Perform Rating Reaffirmed at William Blair

Zoetis (NYSE:ZTS)‘s stock had its “market perform” rating reissued by research analysts at William Blair in a research report issued on Thursday,Benzinga reports.

Other research analysts have also issued reports about the stock. TD Cowen cut their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Morgan Stanley lowered their price objective on shares of Zoetis from $115.00 to $99.00 and set an “overweight” rating for the company in a research report on Wednesday, July 22nd. Citigroup reduced their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Finally, UBS Group reduced their price objective on Zoetis from $99.00 to $85.00 and set a “neutral” rating on the stock in a research note on Monday, July 27th. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $118.33.

Zoetis Price Performance

Shares of NYSE:ZTS traded up $2.31 during mid-day trading on Thursday, reaching $76.70. The stock had a trading volume of 7,813,073 shares, compared to its average volume of 5,676,100. The business’s 50 day moving average price is $76.78 and its 200 day moving average price is $101.29. Zoetis has a 1 year low of $71.47 and a 1 year high of $160.48. The company has a market cap of $32.16 billion, a P/E ratio of 12.87, a price-to-earnings-growth ratio of 1.19 and a beta of 0.74. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.During the same quarter in the previous year, the firm posted $1.76 earnings per share. Zoetis’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts expect that Zoetis will post 6.87 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Frank A. Damelio purchased 6,650 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.

Institutional Investors Weigh In On Zoetis

A number of institutional investors and hedge funds have recently modified their holdings of ZTS. University of Texas Texas AM Investment Management Co. purchased a new stake in Zoetis in the second quarter worth $25,000. Prosperity Bancshares Inc purchased a new position in Zoetis in the 4th quarter worth about $25,000. Cassaday & Co Wealth Management LLC purchased a new position in Zoetis in the 1st quarter worth about $28,000. Root Financial Partners LLC lifted its holdings in Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares in the last quarter. Finally, Elyxium Wealth LLC purchased a new stake in Zoetis in the 4th quarter valued at about $32,000. 92.80% of the stock is owned by institutional investors.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 consensus range and up from $1.76 a year earlier. The earnings beat is likely the primary catalyst supporting the stock. Zoetis Q2 Earnings Beat
• Positive Sentiment: The company maintained strong profitability, reporting a 27.8% net margin and 66.85% return on equity. Its earnings growth despite largely flat revenue may reassure investors about cost management and operating efficiency. Zoetis Earnings Report
• Neutral Sentiment: Zoetis appointed Jay Saccaro as chief financial officer and chief operating officer. The expanded leadership role could improve financial and operational coordination, but investors may wait for more details on his priorities and expected impact. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Management cut fiscal 2026 adjusted EPS guidance to $6.15–$6.25, well below the roughly $6.87 analyst consensus, and reduced revenue guidance to $9.1–$9.3 billion versus approximately $9.8 billion expected. Zoetis Cuts Fiscal 2026 Outlook
• Negative Sentiment: Quarterly revenue declined 0.2% year over year, while softer U.S. pet-healthcare demand, fewer veterinary visits and more price-sensitive customers remain concerns for companion-animal products. Pet Healthcare Demand Slows

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.